Intra-Cellular Therapies, Inc.

NasdaqGS:ITCI Stok Raporu

Piyasa değeri: US$9.1b

Intra-Cellular Therapies Yönetim

Yönetim kriter kontrolleri 2/4

Intra-Cellular Therapies CEO'su Sharon Mates, May2002 tarihinde atandı, in görev süresi 22.5 yıldır. in toplam yıllık tazminatı $ 10.09M olup, şirket hissesi ve opsiyonları dahil olmak üzere 8.8% maaş ve 91.2% ikramiyelerden oluşmaktadır. şirketin hisselerinin 1.01% ine doğrudan sahiptir ve bu hisseler $ 91.72M değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 6.1 yıl ve 10.8 yıldır.

Anahtar bilgiler

Sharon Mates

İcra Kurulu Başkanı

US$10.1m

Toplam tazminat

CEO maaş yüzdesi8.8%
CEO görev süresi22.5yrs
CEO sahipliği1.0%
Yönetim ortalama görev süresi6.1yrs
Yönetim Kurulu ortalama görev süresi10.8yrs

Son yönetim güncellemeleri

Recent updates

Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Nov 07
Revenues Tell The Story For Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) As Its Stock Soars 26%

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Sep 22
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Strong Position To Grow Its Business

Peaking Back In On Intra-Cellular Therapies

Sep 04

Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

Aug 10
Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Just Released Its Second-Quarter Earnings: Here's What Analysts Think

With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Jul 27
With Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) It Looks Like You'll Get What You Pay For

Intra-Cellular Brightens MDD Outlook With Caplyta Success

Jun 19

Intra-Cellular: More Upside Possible Even After Positive MDD Treatment Data

Apr 16

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

Apr 09
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) P/S Is On The Mark

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Mar 17
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Intra-Cellular Therapies Is On Fire

Mar 11

Intra-Cellular Therapies: Buoyant Caplyta Sales And Upcoming MDD Data Support Short-Term 'Buy'

Feb 11

Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

Dec 24
Intra-Cellular Therapies, Inc.'s (NASDAQ:ITCI) Price Is Out Of Tune With Revenues

We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Nov 11
We're Interested To See How Intra-Cellular Therapies (NASDAQ:ITCI) Uses Its Cash Hoard To Grow

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Aug 07
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Can Afford To Invest In Growth

Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

May 09
Here's Why We're Not At All Concerned With Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Situation

After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

Apr 17
After Leaping 31% Intra-Cellular Therapies, Inc. (NASDAQ:ITCI) Shares Are Not Flying Under The Radar

We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Jan 31
We're Not Very Worried About Intra-Cellular Therapies' (NASDAQ:ITCI) Cash Burn Rate

Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Oct 25
Intra-Cellular Therapies (NASDAQ:ITCI) Is In A Good Position To Deliver On Growth Plans

Intra-Cellular Therapies: What Lies Ahead

Sep 20

Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug

Aug 22

Intra-Cellular Therapies GAAP EPS of -$0.92 misses by $0.15, revenue of $55.6M beats by $6.98M

Aug 09

We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Jul 09
We're Hopeful That Intra-Cellular Therapies (NASDAQ:ITCI) Will Use Its Cash Wisely

Intra-Cellular Therapies: A Dramatic Story

Jun 18

Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Apr 03
Companies Like Intra-Cellular Therapies (NASDAQ:ITCI) Are In A Position To Invest In Growth

Intra-Cellular: Not Participating In A Bear Market

Mar 31

Intra-Cellular; Long-Term To Own With A Few FDA Approvals And Ability To Expand

Mar 08

CEO Tazminat Analizi

Sharon Mates'un ücretlendirmesi Intra-Cellular Therapies'un kazancına kıyasla nasıl değişti?
TarihToplam TazminatMaaşŞirket Kazançları
Sep 30 2024n/an/a

-US$86m

Jun 30 2024n/an/a

-US$84m

Mar 31 2024n/an/a

-US$111m

Dec 31 2023US$10mUS$892k

-US$140m

Sep 30 2023n/an/a

-US$155m

Jun 30 2023n/an/a

-US$184m

Mar 31 2023n/an/a

-US$228m

Dec 31 2022US$9mUS$849k

-US$256m

Sep 30 2022n/an/a

-US$298m

Jun 30 2022n/an/a

-US$321m

Mar 31 2022n/an/a

-US$304m

Dec 31 2021US$7mUS$794k

-US$284m

Sep 30 2021n/an/a

-US$259m

Jun 30 2021n/an/a

-US$237m

Mar 31 2021n/an/a

-US$232m

Dec 31 2020US$5mUS$767k

-US$227m

Sep 30 2020n/an/a

-US$207m

Jun 30 2020n/an/a

-US$187m

Mar 31 2020n/an/a

-US$160m

Dec 31 2019US$5mUS$745k

-US$148m

Sep 30 2019n/an/a

-US$148m

Jun 30 2019n/an/a

-US$155m

Mar 31 2019n/an/a

-US$154m

Dec 31 2018US$4mUS$723k

-US$155m

Sep 30 2018n/an/a

-US$145m

Jun 30 2018n/an/a

-US$126m

Mar 31 2018n/an/a

-US$106m

Dec 31 2017US$5mUS$702k

-US$98m

Tazminat ve Piyasa: Sharon 'nin toplam tazminatı ($USD 10.09M ), US pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 7.79M ).

Tazminat ve Kazançlar: Sharon şirketinin tazminatı, şirket kârsız olduğu sürece artırıldı.

CEO

Sharon Mates (71 yo)

22.5yrs

Görev süresi

US$10,086,413

Tazminat

Dr. Sharon Mates, Ph.D. co-founded Intra-Cellular Therapies, Inc. (a/k/a ITI) in May 2002 and was its President until March 19, 2024. She has been Chairman and Chief Executive Officer of Intra-Cellular The...

Liderlik Ekibi

İsimPozisyonGörev süresiTazminatSahiplik
Sharon Mates
Co-Founder22.5yrsUS$10.09m1.01%
$ 91.7m
Michael Halstead
Presidentless than a yearUS$3.53m0%
$ 0
Suresh Durgam
Executive VP & Chief Medical Officer6.3yrsUS$3.51m0.019%
$ 1.7m
Mark Neumann
EVP & Chief Commercial Officer6.1yrsUS$3.54m0.028%
$ 2.5m
Robert Davis
Senior VP & Chief Scientific Officer9yrsUS$2.13mVeri yok
Juan Sanchez
Vice President of Corporate Communications & Investor Relations10.7yrsUS$1.38mVeri yok
Karen Sheehy
Senior VP & Chief Compliance Officer5.3yrsVeri yokVeri yok
John Condon
Senior Vice Presidentno dataVeri yokVeri yok
Michael Olchaskey
Senior VP & Head of Regulatory Affairs6.2yrsVeri yokVeri yok
John Bardi
Senior VP of Market Access5.7yrsVeri yokVeri yok
Willie Earley
Senior VP & Head of Clinical Development2.6yrsVeri yokVeri yok

6.1yrs

Ortalama Görev Süresi

61yo

Ortalama Yaş

Deneyimli Yönetim: ITCI 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.1 yıldır).

Yönetim Kurulu Üyeleri

İsimPozisyonGörev süresiTazminatSahiplik
Sharon Mates
Co-Founder11.3yrsUS$10.09m1.01%
$ 91.7m
Rory Riggs
Independent Director10.8yrsUS$470.51k0.11%
$ 10.0m
Robert Van Nostrand
Lead Independent Director10.8yrsUS$507.58k0.011%
$ 972.1k
Joel Marcus
Independent Director11.3yrsUS$473.34k0.039%
$ 3.5m
Carol Tamminga
Chairman of Medical Advisory Boardno dataVeri yokVeri yok
John Kane
Member of Medical Advisory Boardno dataVeri yokVeri yok
Jeffrey Lieberman
Member of Medical Advisory Boardno dataVeri yokVeri yok
Christoph Correll
Member of Medical Advisory Boardno dataVeri yokVeri yok
Donald Goff
Member of Medical Advisory Boardno dataVeri yokVeri yok
Eduardo Salas
Independent Director2.6yrsUS$461.30k0.0015%
$ 134.5k

10.8yrs

Ortalama Görev Süresi

71yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: ITCI 'in yönetim kurulu deneyimli ve tecrübelidir (ortalama görev süresi 10.8 yıldır).